Tax1bp1-deficiency decreases the frequency of microabscess formation and lymphocyte depletion during <i>L. monocytogenes</i> infection. by Jeffrey Chin (22538086)

Pre-RT and post RT D-dimer levels in associated with prognostic significance. by Huriye Senay Kiziltan (22298378)

Subjects:

The inhibitory activity of the most active compounds against Glo-I enzyme with less than 50 µM. Their supportive corresponding docking values on two different protocols are display... by MohammedBashar Al-Qazzan (22439236)

The effect of pre-RT D-dimer levels on post-RT changes in D-dimer levels and on survival rates. by Huriye Senay Kiziltan (22298378)

Subjects:

ROC curve according to their D-dimer values in patients with PFS ≥ 1 year and those with PFS < 1 year. p < 0.001 (95% CI: 4-21). by Huriye Senay Kiziltan (22298378)

Subjects:

Kaplan Meier curves of OS and PFS according to RT and/or CRT response. by Huriye Senay Kiziltan (22298378)

Subjects:

Univariate and multivariable analyses for progression free survival. by Huriye Senay Kiziltan (22298378)

Subjects:

Kaplan Meier curves of OS and PFS according to different pre-RT different D-dimer values. by Huriye Senay Kiziltan (22298378)

Subjects:

Univariate and multivariable analyses for OS. by Huriye Senay Kiziltan (22298378)

Subjects:

Characteristics of LC patients. by Huriye Senay Kiziltan (22298378)

Subjects:

Decision curve analysis according to t D-dimer values in patients with OS ≥ 1 year and those with OS < 1 year. by Huriye Senay Kiziltan (22298378)

Subjects:

Kaplan Meier curves of OS and PFS according to d-dimer values comparing OS rates between patients with D-dimer levels ≤ 0.3 µg/mL and those with levels > 0.3 µg/mL. by Huriye Senay Kiziltan (22298378)

Subjects:

ROC curve according to their D-dimer values in patients with OS ≥ 1 year and those with OS < 1 year. p < 0.001 (95% CI: 6-24). by Huriye Senay Kiziltan (22298378)

Subjects:

Flowchart of this study. by Huriye Senay Kiziltan (22298378)

Subjects:

RT characteristics and D-dimer, OS and PFS of patients. by Huriye Senay Kiziltan (22298378)

Subjects:

Combination of intraperitoneal and intratumoral administration of vitamin D3 is more effective in reducing the EAC tumor volume compared to just i.p. administration: by Vidya G. Bettada (22208808)

“…Administration of cisplatin (2.5 mg/Kg) and vitamin D3 (125 µg/Kg) significantly decreased the vessel density (CD31) compared to the tumor control group.…”

Mice in the NTC and MBC-005 treatment groups were evaluated for bioluminescent signaling at 6-, 13-, and 21-days after tumor inoculation. by Bryan S. Margulies (21492667)

Study data. by Jie Liu (15128)

“…</p><p> Conclusion </p><p>During the COVID-19 pandemic, both roxadustat and ESAs effectively improved renal anemia in PD patients, however, the roxadustat group experienced less additional costs for anemia correction and better medication compliance.…”

Summary of clinical outcomes after 9 months. by Jie Liu (15128)

“…</p><p> Conclusion </p><p>During the COVID-19 pandemic, both roxadustat and ESAs effectively improved renal anemia in PD patients, however, the roxadustat group experienced less additional costs for anemia correction and better medication compliance.…”

Approval by the research ethics committee. by Jie Liu (15128)

“…</p><p> Conclusion </p><p>During the COVID-19 pandemic, both roxadustat and ESAs effectively improved renal anemia in PD patients, however, the roxadustat group experienced less additional costs for anemia correction and better medication compliance.…”